SEXUAL HEALTH & VITALITY RESEARCH
Bremelanotide — a melanocortin receptor agonist that acts on the brain to trigger sexual arousal and desire.
PT-141 (bremelanotide) is a melanocortin receptor agonist that acts centrally to trigger sexual arousal and desire—distinct from PDE5 inhibitors that only affect blood flow. It is FDA-approved in its clinical formulation for hypoactive sexual desire disorder.
Included because it is FDA-approved in its clinical formulation, works through a well-characterized central melanocortin mechanism, and has measurable outcomes in sexual-desire research. It anchors the established end of the sexual-health research spectrum.
Binds MC4R receptors in the central nervous system.
Activates the brain's sexual-arousal pathway, increasing desire and sensitivity.
Acts centrally rather than on peripheral blood flow, and is studied in both men and women.
WHAT THE RESEARCH MEASURED
Findings describe study outcomes, not expected personal results.
PT-141 (bremelanotide) is FDA-approved in its clinical formulation. Material offered here is sold and offered strictly for laboratory and research use.
